Allergic Rhinitis

42
Pipeline Programs
21
Companies
39
Clinical Trials
11
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
9
0
9
1
5
18
Early DiscoveryClinical DevelopmentMarket

On Market (11)

Approved therapies currently available

U
ALAVERTApproved
loratadine
Unknown Company
oral2002
U
ASTELINApproved
azelastine hydrochloride
Unknown Company
nasal1996
U
AZELASTINE HYDROCHLORIDE ALLERGYApproved
azelastine hydrochloride
Unknown Company
nasal2025
U
AZELASTINE HYDROCHLORIDE CHILDREN'S ALLERGYApproved
azelastine hydrochloride
Unknown Company
nasal2024
Bayer
CHILDREN'S CLARITINApproved
loratadine
Bayer
oral2006
Bayer
CLARITINApproved
loratadine
Bayer
oral2008
Bayer
CLARITIN HIVES RELIEFApproved
loratadine
Bayer
oral1996
Bayer
CLARITIN HIVES RELIEF REDITABApproved
loratadine
Bayer
oral1996
Bayer
CLARITIN REDITABSApproved
loratadine
Bayer
oral2006
U
LORATADINEApproved
loratadine
Unknown Company
oral2019
U
OPTIVARApproved
azelastine hydrochloride
Unknown Company
ophthalmic2000

Competitive Landscape

20 companies ranked by most advanced pipeline stage

Hal Allergy
Hal AllergyNetherlands - Leiden
6 programs
4
2
PURETHAL Birch, 20.000 AUM/mlPhase 41 trial
PURETHAL Grasses, 20.000 AUM/mlPhase 41 trial
PURETHAL Mites 20,000 AUeq/mlPhase 21 trial
SUBLIVAC FIX BirchPhase 21 trial
SUBLIVAC FIX Phleum Prat.Phase 21 trial
+1 more programs
Active Trials
NCT00973453Completed48Est. Aug 2010
NCT01639768Completed270Est. Apr 2013
NCT02556801Completed168Est. Oct 2016
+3 more trials
UP
UCB PharmaBelgium - Brussels
4 programs
1
2
1
LevocetirizinePhase 41 trial
LevocetirizinePhase 31 trial
Levocetirizine 1.25 mgPhase 31 trial
Levocetirizine oral solutionPhase 21 trial
Active Trials
NCT00152412Completed30Est. Dec 2004
NCT00619801Completed173Est. Jul 2008
NCT00628108Completed69Est. Sep 2008
+1 more trials
Alcon
AlconFORT WORTH, TX
2 programs
1
1
Olopatadine 0.6% / Azelastine 137 mcgPhase 41 trial
Olopatadine Hydrochloride Nasal Spray 0.6%Phase 21 trial
Active Trials
NCT00794144Completed132
NCT00772304Completed
Bayer
BayerLEVERKUSEN, Germany
2 programs
1
1
LoratadinePhase 41 trial
Azelastine hydrochloridePhase 31 trial
Active Trials
NCT04264637Completed110Est. Mar 2021
NCT04162795Completed468Est. Nov 2019
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
1
Cetirizine Hydrochloride 1 MG/MLPhase 41 trial
Active Trials
NCT03340740CompletedEst. Aug 2021
Sanofi
SanofiPARIS, France
1 program
1
FexofenadinePhase 41 trial
Active Trials
NCT00636870Completed220Est. Jan 2004
Marinomed Biotech
Marinomed BiotechAustria - Korneuburg
3 programs
1
RhinocortPhase 31 trial
nasal sprayN/A1 trial
nasal sprayN/A1 trial
Active Trials
NCT04532762Completed42Est. Dec 2020
NCT04531358Completed42Est. Dec 2020
NCT03755557Completed82Est. Apr 2019
Teva
TevaIsrael - Petach Tikva
2 programs
1
1
BDPPhase 32 trials
BDP HFA Nasal AerosolPhase 11 trial
Active Trials
NCT01537692Completed30Est. Jun 2009
NCT01783548Completed547Est. Oct 2013
NCT01697956Completed99Est. Feb 2013
Stallergenes Greer
Stallergenes GreerFrance - Antony
2 programs
1
300 IR house dust mites allergen extract tabletPhase 2/31 trial
Evaluation of the Benefits of Sublingual AIT (PRACTIS)N/A1 trial
Active Trials
NCT06574061Completed1,635Est. Oct 2021
NCT00674700Completed509Est. Feb 2010
M&
Merck & Co.RAHWAY, NJ
3 programs
1
epinastine 0.1%Phase 21 trial
Diesel Exhaust Particles and Leukotriene ProductionN/A1 trial
Swab of vestibule and middle meatus of noseN/A1 trial
Active Trials
NCT00915447Withdrawn0Est. Apr 2013
NCT01461200Completed40Est. Feb 2012
NCT01382654Completed131Est. Oct 2006
Orexo
OrexoNJ - Morristown
1 program
1
BLX-028914Phase 21 trial
Active Trials
NCT00758446CompletedEst. Jan 2009
Regeneron
RegeneronTARRYTOWN, NY
1 program
1
REGN5713Phase 21 trial
Active Trials
NCT05430919Completed217Est. Jul 2023
Novartis
NovartisBASEL, Switzerland
2 programs
1
NVP-VAK694Phase 11 trial
Dust mite extract, Fluticasone, MethacholineN/A1 trial
Active Trials
NCT00513487Completed18Est. Nov 2007
NCT00620230Completed46Est. Apr 2008
GS
Gilead SciencesFOSTER CITY, CA
2 programs
2
CAL-101Phase 12 trials
CAL-101Phase 1
Active Trials
NCT02445131Completed48Est. Mar 2022
NCT00836914Completed41Est. Mar 2009
Amber Therapeutics
1 program
1
Grass pollen extractPhase 11 trial
Active Trials
NCT01982474UnknownEst. Dec 2016
Pfizer
PfizerNEW YORK, NY
1 program
1
IGE-1Phase 11 trial
Active Trials
NCT01723254Completed190Est. Jun 2015
CT
1 program
1
TQC3564 tabletsPhase 11 trial
Active Trials
NCT05607446TerminatedEst. Dec 2023
Xencor
XencorPASADENA, CA
1 program
1
XmAb7195Phase 11 trial
Active Trials
NCT02148744CompletedEst. Sep 2015
J&
Johnson & JohnsonNEW BRUNSWICK, NJ
1 program
1
diphenhydramine HClPhase 11 trial
Active Trials
NCT00762749Completed36Est. Nov 2008
Bial
BialPortugal - Coronado
1 program
InjexN/A1 trial
Active Trials
NCT02965612UnknownEst. May 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BayerLoratadine
City TherapeuticsCetirizine Hydrochloride 1 MG/ML
Hal AllergyPURETHAL Birch, 20.000 AUM/ml
Hal AllergyPURETHAL Grasses, 20.000 AUM/ml
AlconOlopatadine 0.6% / Azelastine 137 mcg
UCB PharmaLevocetirizine
SanofiFexofenadine
BayerAzelastine hydrochloride
Marinomed BiotechRhinocort
TevaBDP
TevaBDP
UCB PharmaLevocetirizine
UCB PharmaLevocetirizine 1.25 mg
Stallergenes Greer300 IR house dust mites allergen extract tablet
RegeneronREGN5713

Showing 15 of 39 trials with date data

Clinical Trials (39)

Total enrollment: 6,077 patients across 39 trials

A Study to Evaluate Cooling Sensation of an Allergy Product in Adults With a History of Allergies

Start: Nov 2019Est. completion: Nov 2019468 patients
Phase 4Completed
NCT03340740City TherapeuticsCetirizine Hydrochloride 1 MG/ML

The Effect of Cetirizine on Bronchoconstriction

Start: May 2018Est. completion: Aug 2021
Phase 4Completed
NCT01918956Hal AllergyPURETHAL Birch, 20.000 AUM/ml

PURETHAL Birch RUSH Study

Start: Sep 2013Est. completion: Apr 2014120 patients
Phase 4Completed
NCT01059266Hal AllergyPURETHAL Grasses, 20.000 AUM/ml

PURETHAL Grasses Rush Study

Start: Feb 2010Est. completion: Sep 2010150 patients
Phase 4Completed
NCT00772304AlconOlopatadine 0.6% / Azelastine 137 mcg

Evaluation of the Sensory Attributes of Olopatadine 0.6% and Azelastine 137mcg Nasal Sprays in Patients w/Allergic Rhinitis

Start: Oct 2008
Phase 4Completed
NCT00355771UCB PharmaLevocetirizine

Levocetirizine 5 mg: Reduction of Symptoms, Airway Resistance and Sleep Impairment in Persistent Allergic Rhinitis

Start: Jun 2006Est. completion: Nov 2007100 patients
Phase 4Completed
NCT00636870SanofiFexofenadine

Fexofenadine (Allegra®) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine

Start: Feb 2003Est. completion: Jan 2004220 patients
Phase 4Completed
NCT04264637BayerAzelastine hydrochloride

Study to Find Out How Long it Takes Azelastine Hydrochloride 0.15% Nasal Spray to Relieve Symptoms in Patients Suffering From Allergic Rhinitis

Start: Feb 2020Est. completion: Mar 2021110 patients
Phase 3Completed

Demonstration of Equivalence and Early Onset of a Novel Anti-allergic Nasal Spray Compared to Marketed Nasal Spray

Start: Nov 2018Est. completion: Apr 201982 patients
Phase 3Completed

Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR)

Start: Jan 2013Est. completion: Oct 2013547 patients
Phase 3Completed

Hypothalamic-Pituitary-Adrenal (HPA)-Axis Study in Pediatric Subjects With Perennial Allergic Rhinitis (PAR)

Start: Oct 2012Est. completion: Feb 201399 patients
Phase 3Completed
NCT00619801UCB PharmaLevocetirizine

Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin

Start: Mar 2008Est. completion: Jul 2008173 patients
Phase 3Completed
NCT00628108UCB PharmaLevocetirizine 1.25 mg

Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months

Start: Mar 2008Est. completion: Sep 200869 patients
Phase 3Completed
NCT00674700Stallergenes Greer300 IR house dust mites allergen extract tablet

Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis

Start: Oct 2007Est. completion: Feb 2010509 patients
Phase 2/3Completed

Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants

Start: Aug 2022Est. completion: Jul 2023217 patients
Phase 2Completed
NCT02556801Hal AllergySUBLIVAC FIX Phleum Prat.

Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy

Start: Sep 2015Est. completion: Oct 2016168 patients
Phase 2Completed

Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)

Start: May 2015Est. completion: Mar 202248 patients
Phase 2Completed
NCT01682070Hal AllergySUBLIVAC FIX phleum prat.

SUBLIVAC FIX Phleum Pratense DT/DRF

Start: Sep 2012Est. completion: May 2013266 patients
Phase 2Completed
NCT01639768Hal AllergySUBLIVAC FIX Birch

SUBLIVAC FIX Birch Dose Tolerability/Dose Range Finding

Start: Jul 2012Est. completion: Apr 2013270 patients
Phase 2Completed
NCT00973453Hal AllergyPURETHAL Mites 20,000 AUeq/ml

Study With High Dose PURETHAL Mites in Allergic Rhinitis/Rhinoconjunctivitis Patients

Start: Aug 2009Est. completion: Aug 201048 patients
Phase 2Completed
NCT00794144AlconOlopatadine Hydrochloride Nasal Spray 0.6%

Safety and Pharmacokinetics of Patanase in Pediatric Patients 2 to < 6 Years of Age

Start: Oct 2008132 patients
Phase 2Completed

Efficacy and Safety Study of BLX-028914 in Subjects With Allergic Rhinitis

Start: Sep 2008Est. completion: Jan 2009
Phase 2Completed
NCT01382654Merck & Co.epinastine 0.1%

Two Formulations and Concentrations of Epinastine Nasal Spray Versus Azelastine Nasal Solution for Allergic Rhinitis

Start: Sep 2006Est. completion: Oct 2006131 patients
Phase 2Completed
NCT00152412UCB PharmaLevocetirizine oral solution

Open Study to Evaluate the Safety of Levocetirizine in Young Children (2 - 6 Years) Suffering From Allergic Rhinitis

Start: Jun 2004Est. completion: Dec 200430 patients
Phase 2Completed

To Evaluate the Efficacy and Safety of TQC3564 Tablets in the Treatment of Persistent Allergic Rhinitis

Start: Sep 2022Est. completion: Dec 2023
Phase 1Terminated

Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis

Start: May 2014Est. completion: Sep 2015
Phase 1Completed
NCT01982474Amber TherapeuticsGrass pollen extract

Safety of Lymph Node Injection for Allergen Immunotherapy

Start: Oct 2013Est. completion: Dec 2016
Phase 1Unknown

A Study To Assess The Safety And Tolerability Of Different Doses Of PF-06444753 And PF-06444752 In Subjects With Allergic Rhinitis

Start: Dec 2012Est. completion: Jun 2015190 patients
Phase 1Completed
NCT01537692TevaBDP HFA Nasal Aerosol

Clinical Study to Evaluate the Pharmacokinetics and Safety of BDP HFA Nasal Aerosol

Start: Mar 2009Est. completion: Jun 200930 patients
Phase 1Completed

Study to Investigate Effects of CAL-101 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber

Start: Feb 2009Est. completion: Mar 200941 patients
Phase 1Completed
NCT00762749Johnson & Johnsondiphenhydramine HCl

Study to Evaluate Diphenhydramine in Children and Adolescents

Start: Sep 2008Est. completion: Nov 200836 patients
Phase 1Completed

Safety and Tolerability of Single and Multiple Doses of VAK694 in Healthy and Atopic Subjects

Start: Oct 2007Est. completion: Apr 200846 patients
Phase 1Completed

Demonstration of a Decongestant Effect of "Coldamaris Akut" Compared to Saline Nasal Spray.

Start: Aug 2020Est. completion: Dec 202042 patients
N/ACompleted

Demonstration of an Anti-allergic Effect in Subjects Treated With Callergin Nasal Spray in Comparison to Untreated Subjects and Subjects Treated With Vis Alpin® Alpensalz Nasal Spray, All Suffering From Grass Pollen Induced Rhinitis/Rhinoconjunctivitis

Start: Aug 2020Est. completion: Dec 202042 patients
N/ACompleted
NCT06574061Stallergenes GreerEvaluation of the Benefits of Sublingual AIT (PRACTIS)

Evaluation of the Benefits of Sublingual AIT (PRACTIS)

Start: Aug 2018Est. completion: Oct 20211,635 patients
N/ACompleted

Specific Immunotherapy for Allergic Child

Start: May 2015Est. completion: May 2017
N/AUnknown
NCT01461200Merck & Co.Swab of vestibule and middle meatus of nose

Effects of Allergic Rhinitis on the Nasal/Sinus Microbiome

Start: Mar 2011Est. completion: Feb 201240 patients
N/ACompleted
NCT00915447Merck & Co.Diesel Exhaust Particles and Leukotriene Production

Diesel Exhaust Particles and Leukotriene Production

Start: Apr 2008Est. completion: Apr 20130
N/AWithdrawn
NCT00513487NovartisDust mite extract, Fluticasone, Methacholine

Effects of Multiple Nasal Exposures to House Dust Mite Allergen on Nasal and Body Inflammation and Airway Sensitivity

Start: Jul 2007Est. completion: Nov 200718 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

5 late-stage (Phase 3) programs — potential near-term approvals
21 companies competing in this space